Search results
Dupixent set for FDA review in adolescent chronic inflammatory sinus disease
Pharmaceutical Technology via Yahoo Finance· 17 hours agoRegeneron and Sanofi could soon be adding another indication to its blockbuster immunology drug...
Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
Zacks via Yahoo Finance· 18 hours agoSanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with...
Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids
Zacks via Yahoo Finance· 1 year agoSanofi (SNY) and Regeneron's Dupixent becomes the first and only targeted medicine approved to treat...
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
Investor's Business Daily· 6 months agoRegeneron Pharmaceuticals and Sanofi said Monday their blockbuster drug, Dupixent, significantly...
Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL
Zacks via Yahoo Finance· 1 year agoThis week, Sanofi SNY and partner Regeneron’s REGN blockbuster medicine, Dupixent succeeded in a...
US FDA approves Dupixent to treat younger kids with esophageal condition
Reuters via AOL· 4 months ago(Reuters) -The U.S. health regulator has approved the use of Regeneron and Sanofi's Dupixent to...
Sanofi forecasts moderate profit growth on Dupixent demand
Reuters via Yahoo News· 1 year ago(Reuters) -Sanofi forecast moderate earnings growth that undershot expectations, saying demand for...
Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples
Investor's Business Daily· 1 year agoRegeneron stock surged Friday on stronger-than-expected metrics, though its partner Sanofi posted a...
Sanofi Raises Profit Guide And Reverses A Drug-Pricing Pitfall
Investor's Business Daily· 2 years agoSanofi stock ended flat Thursday — reversing earlier declines — despite lifting its profit guidance...
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
Zacks via Yahoo Finance· 2 months agoASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with...